When Cytiva recently surveyed the biopharma industry to gain insights into sustainability progress, there was good news and bad news. Companies are succeeding in managing Scope 1 and 2 carbon emissions (Scope 1 covers direct emissions from owned or controlled sources, while Scope 2 covers indirect emissions resulting from the purchase of electricity, steam, heat or cooling)—but when it comes to Scope 3, struggles persist.
Read more...
About the Author
EcoVadis is a purpose-driven company dedicated to embedding sustainability intelligence into every business decision worldwide. With global, trusted and actionable ratings, businesses of all sizes rely on EcoVadis’ detailed insights to comply with ESG regulations, reduce GHG emissions, and improve the sustainability performance of their business and value chain across 220 industries in 180 countries. Leaders like Johnson & Johnson, L’Oréal, Unilever, Bridgestone, BASF and JPMorgan are among 150,000+ businesses that use EcoVadis ratings, risk, and carbon management tools and e-learning platform to accelerate their journey toward resilience, sustainable growth and positive impact worldwide.
Follow on Linkedin
Visit Website
More Content by EcoVadis EN
